Catalyst Biosciences Inc (NASDAQ:CBIO) – Equities research analysts at B. Riley upped their FY2017 EPS estimates for shares of Catalyst Biosciences in a research report issued on Monday. B. Riley analyst G. Zavoico now anticipates that the biopharmaceutical company will post earnings of ($7.85) per share for the year, up from their prior estimate of ($8.19). B. Riley has a “Buy” rating and a $49.00 price objective on the stock. B. Riley also issued estimates for Catalyst Biosciences’ Q4 2017 earnings at ($1.41) EPS, Q1 2018 earnings at ($1.30) EPS, Q2 2018 earnings at ($1.32) EPS, Q3 2018 earnings at ($1.42) EPS, Q4 2018 earnings at ($1.50) EPS, FY2018 earnings at ($5.57) EPS, FY2019 earnings at ($7.04) EPS, FY2020 earnings at ($9.13) EPS and FY2021 earnings at ($6.48) EPS.
Several other equities research analysts have also commented on CBIO. ValuEngine upgraded shares of Catalyst Biosciences from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd. Zacks Investment Research lowered shares of Catalyst Biosciences from a “buy” rating to a “hold” rating in a report on Monday, January 1st. Finally, Chardan Capital boosted their price target on shares of Catalyst Biosciences from $10.00 to $75.00 and gave the company a “buy” rating in a report on Friday, February 9th. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $37.50.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Virtu KCG Holdings LLC bought a new position in shares of Catalyst Biosciences during the 2nd quarter worth approximately $103,000. Bank of New York Mellon Corp purchased a new stake in Catalyst Biosciences during the 2nd quarter worth approximately $107,000. Geode Capital Management LLC purchased a new stake in Catalyst Biosciences during the 4th quarter worth approximately $379,000. Vanguard Group Inc. grew its position in Catalyst Biosciences by 294.1% during the 2nd quarter. Vanguard Group Inc. now owns 43,714 shares of the biopharmaceutical company’s stock worth $204,000 after purchasing an additional 32,621 shares during the last quarter. Finally, Dimensional Fund Advisors LP purchased a new stake in Catalyst Biosciences during the 2nd quarter worth approximately $372,000. Hedge funds and other institutional investors own 22.90% of the company’s stock.
About Catalyst Biosciences
Catalyst Biosciences, Inc, formerly Targacept, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness.
Receive News & Ratings for Catalyst Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.